Evaluation and Mitigation of Time‐Dependent Confounding Effects in Conventional Exposure‐Response Analyses for Oncology Drugs
Conventional exposure-response (E-R) analyses, such as logistic regression and time-to-event analysis using summary exposure metrics, are often conducted in oncology using data from the pivotal trial(s) with a single dose level to support dosing decisions. However, these E-R analyses, affected by multiple confounding factors, may mischaracterize true E-R relationships, potentially limiting their utility in dosing decisions. This study investigates potential mischaracterization in such analyses influenced by the following time-dependent confounding factors: exposure accumulation, dose modification patterns, and event onset time. We used a simulation-based approach to evaluate two E-R scenarios: ER1, where event time generated with a Weibull distribution is not affected by drug exposure, and ER2, where the response is driven by drug exposure via a joint PK-tumor size model. Our analyses indicate that when using time-dependent exposure metrics (e.g., average concentration till event/censoring), exposure accumulation tends to induce an inverse E-R trend, while dose modifications (interruptions/reductions) likely induce a positive E-R trend. Simulations suggest that employing static exposure metrics (e.g., first-cycle or steady-state) minimizes these biases. Additionally, adopting an Emax model aligned with the underground truth in ER2 in the E-R analyses could reduce bias. When significant dose modifications are present, including relevant data from a dose-range study and employing modified methods for time-dependent exposure derivation may help mitigate bias. Overall, using multiple exposure metrics (including static ones) to assess E-R consistency and interpreting the potential causal effects with totality of evidence (including dose-response results) should be implemented to better inform dosing decisions.
Authors
- Rajanikanth Madabushi (ORCID: https://orcid.org/0000-0001-8686-9652)
- Xin Wei (ORCID: https://orcid.org/0000-0003-4213-451X)
- Amal Ayyoub
- Jiang Liu (ORCID: https://orcid.org/0000-0002-5755-3904)
- Stephan Schmidt (ORCID: https://orcid.org/0000-0002-4998-1167)
- Elimika Pfuma Fletcher (ORCID: https://orcid.org/0000-0002-0345-4230)
- Ye Xiong (ORCID: https://orcid.org/0000-0002-4473-0393)
- Youwei Bi (ORCID: https://orcid.org/0000-0001-5626-2403)
- Hong Zhao (ORCID: https://orcid.org/0000-0002-5253-6638)
- Hao‐Jie Zhu (ORCID: https://orcid.org/0000-0002-2248-4419)
- Xuefen Yin (ORCID: https://orcid.org/0009-0006-1653-9192)
Institutions
- United States Food and Drug Administration (US)
- Center for Drug Evaluation and Research (US)
- University of Florida (US)
Publication Details
- Journal
- CPT Pharmacometrics & Systems Pharmacology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1002/psp4.70119
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.00